The article delves into the limitations of governance agreements with large CROs, questioning their effectiveness when it comes to holding the CRO accountable. While these agreements are designed to provide security, they often fail to offer real solutions if the CRO underperforms, leaving smaller biotech and pharmaceutical companies in difficult positions. It emphasizes the importance of ensuring true collaboration and accountability beyond contractual terms.
